The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring ...

Novavax (NASDAQ: NASDAQ:NVAX) stock plummeted 24% after comments from Health and Human Services Secretary Robert F. Kennedy Jr. suggested a shift in government priorities away from the company’s ...

Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

What should investors do during a market downturn? Some might resort to panic selling, but that's hardly a good strategy.

U.S. stocks were lower, with the Dow Jones index dipping over 800 points on Thursday. Pricesmart reported quarterly earnings ...

Investing.com-- U.S. stocks fell sharply Thursday after investors digested relatively benign inflation data amid continuing ...

Shares traded 8.5% higher at $72.55. The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...